A Clinical Curative Effect Analysis Induced By TACE Combined With Hepatic Arterial Perfusion Chemotherapy For Patients With Colorectal Liver Metastases

Purpose:The liver is colorectal cancer(CRC)common distant metastasis of organs,the only curative therapy is surgical resection,but 80%-90% patients for various reasons can not accept surgical intervention,because of their advantages of common concern.In this study,through observation,analysis and application of raltitrexed for hepatic artery perfusion chemotherapy(TAI)plus chemotherapy embolization(TACE)for the treatment of colorectal liver metastases(CRCLM)the recent efficacy and safety,and lay the foundation for further research,hope to promote the application of TACE based combination in the treatment of CRCLM.Methods:During the period from January 2013 to August 2016,23 CRCLM patients in the interventional ward of the First Affiliated Hospital of Shanxi Medical University were selected to receive at least 2 cycles of chemotherapy patients,but still in progress.Using the technology of Seldinger super selective hepatic metastasis of artery,the first 50 milli J Asha Leigh Per slow and the amount of lipiodol mixture was injected into the filling after the micro catheter,in the metastasis related responsible vessels,by in vitro micro catheter continuous infusion chemotherapy(oxaliplatin has raltitrexed 100 mg and 3 mg),efficacy and adverse reactions were recorded in patients with postoperative 4-6 weeks after upper abdominal CT or MRI evaluation.Results:1.According to the latest standard of curative effect after interventional therapy of solid tumors: CR 0 cases of complete remission,partial remission in 8 cases of PR(34.78%),stable disease and 11 cases of SD(47.83%),4 cases of disease progression in PD(17.39%),effective 8 cases of RR(34.78%),disease control rate of DCR in 19 cases(82.61%).2.According to the number of metastasis group,including 3 cases of metastatic < 0CR,PR 1 cases(20%),SD(60%)3 cases,PD 1 cases(20%),RR(20%)1 cases,DCR 4cases(80%);more than 3 metastasis CR 0 cases,PR 7 cases SD(38.39%),8 cases(44.44%),PD(16.67%)3 cases,RR 7 cases(38.89%),15 cases of DCR(83.33%).The efficiency of the two groups,the disease control rate of P was greater than 0.05,no significant differences between the groups.3.A total of 62 patients were treated after surgery,there were no serious adverse reactions.There are different degrees of embolization within 3 days after surgery in most cases after syndrome,manifested as liver discomfort(37,59.68%),pain(36,58.06%),nausea and vomiting(29,46.77%),Na the difference(41,66.13%),fatigue(30,48.39%)and fever(36,58.06%),symptomatic treatment after 1 to 2 weeks to ease soon.There are12 patients with allergic reactions of unknown causes,positive anti allergy treatment after1 to 2 days away.Conclution:1.Raltitrexed combined with oxaliplatin in hepatic artery perfusion chemotherapy(TAI)and hepatic artery chemoembolization(TACE)for the treatment of colorectal liver metastases(CRCLM)positive curative effect,no toxic side effects,and is worthy of further clinical research.2.For patients with progressive CRCLM systemic chemotherapy,a combination of hepatic arterial infusion chemotherapy(TAI)and transcatheter arterial chemoembolization(TACE)provides an alternative option.In the treatment of livermetastases from colorectal cancer,it has good effect and low side effects,which is worthy of promotion.3.This medicine(Raltitrexed)has a better effect in the treatment of CRCLM,and the side effect is low,so it needs further study.